<SUBMISSION>
<ACCESSION-NUMBER>0000950148-02-002847
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20021203
<ITEMS>5
<ITEMS>7
<FILING-DATE>20021203
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<STATE-OF-INCORPORATION>NV
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>02847640
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v86330e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Advanced Biotherapy, Inc. Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<P align="center"><FONT size="2"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, DC 20549</B></FONT>

<P align="center"><FONT size="2"><B>FORM 8-K</B></FONT>

<P align="center"><FONT size="2"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B></FONT>

<P align="left"><FONT size="2">Date of Report (Date of earliest reported) December&nbsp;3, 2002</FONT>

<P align="center"><FONT size="2">Advanced Biotherapy, Inc.</FONT>

<HR width="36%" align="center" size="1" noshade>

<DIV align="center"><FONT size="2">(Exact name of registrant as specified in its chapter)</FONT></DIV>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="34%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="28%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">Delaware</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">0-26323</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">95-0402415</FONT></TD>
</TR>
<TR>
    <TD align="center" valign="top"><HR size="1" noshade></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2"><HR size="1" noshade></FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><FONT size="2">(State or other jurisdiction<BR>of incorporation)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">(Commission<BR>File Number)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="top"><FONT size="2">(IRS Employer<BR>Identification No.)</FONT></TD>
</TR>
</TABLE>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="bottom"><FONT size="2">6355 Topanga Canyon Boulevard, Suite&nbsp;510<BR>Woodland Hills, California<BR><HR size="1" noshade>
(Address of principal executive offices)</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="center" valign="bottom"><FONT size="2"><BR>91367<HR size="1" noshade>
(Zip Code)</FONT></TD>
</TR>
</TABLE>
<P align="center"><FONT size="2">Registrant&#146;s telephone number, including area code (818)&nbsp;883-6716</FONT>

<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>


<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;5. OTHER EVENTS.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signatures</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">INDEX TO EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="v86330exv99w1.htm">Exhibit 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>






<!-- link2 "Item&nbsp;5. OTHER EVENTS." -->
<DIV align="left"><A NAME="000"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;5. OTHER EVENTS.</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant published a press release on December&nbsp;2, 2002, which
reported that Advanced Biotherapy, Inc. has received a Notice of Allowance from
the United States Patent and Trademark Office for a utility patent for the use
of any form of antibody to gamma interferon to treat corneal transplant
rejection.
</FONT>
<!-- link2 "Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>
<P align="left"><FONT size="2">Item&nbsp;7. FINANCIAL STATEMENTS AND EXHIBITS</FONT>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">
<TR valign="top">
   <TD width="1%" align="right" nowrap><FONT size="2">(c)</FONT></TD>
   <TD width="1%" nowrap><FONT size="2">&nbsp;&nbsp;</FONT></TD>
   <TD width="98%"><FONT size="2">Exhibits.</FONT></TD>
</TR>
</TABLE>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><FONT size="1">Designation</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1">Description of Exhibit</FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">99.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Press Release, dated December&nbsp;2, 2002</FONT></TD>
</TR>
</TABLE>
<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="002"></A></DIV>
<P align="center"><FONT size="2">Signatures</FONT>

<P><FONT size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
</FONT>
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR>
        <TD width="50%">&nbsp;</TD>
        <TD width="1%">&nbsp;</TD>
        <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD colspan="2"><FONT size="2">ADVANCED BIOTHERAPY, INC.<BR>(Registrant)</FONT></TD>
</TR>

<TR><TD>&nbsp;<BR>&nbsp;</TD></TR>
<TR valign="top">
    <TD><FONT size="2">Date: December&nbsp;2, 2002</FONT></TD>
    <TD><FONT size="2">By:&nbsp;</FONT></TD>
    <TD align="left"><FONT size="2">/s/Edmond Buccellato</FONT></TD>
</TR>
<TR>
        <TD colspan="2"><FONT size="1">&nbsp;</FONT></TD>
        <TD><HR size="1" noshade color="#000000"></TD>
</TR>
<TR valign="top">
    <TD colspan="2">&nbsp;</TD>
    <TD><FONT size="2">Edmond Buccellato, President and CEO</FONT></TD>
</TR>
</TABLE>

<!-- link1 "INDEX TO EXHIBITS" -->
<DIV align="left"><A NAME="003"></A></DIV>
<P align="center"><FONT size="2">INDEX TO EXHIBITS</FONT>

<TABLE cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="9%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><FONT size="1">Exhibit</FONT></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><FONT size="1">Description</FONT></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="center"><HR size="1" noshade></TD>
    <TD><FONT size="1">&nbsp;</FONT></TD>
    <TD nowrap align="center"><HR size="1" noshade></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><FONT size="2">99.1</FONT></TD>
    <TD><FONT size="2">&nbsp;</FONT></TD>
    <TD align="left" valign="top"><FONT size="2">
Text of Press Release, dated December&nbsp;2, 2002</FONT></TD>
</TR>
</TABLE>
<P align="center"><FONT size="2">&nbsp;
</FONT>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v86330exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<P align="right"><FONT size="2">EXHIBIT 99.1</FONT>

<P><FONT size="2"><B>Advanced Biotherapy Inc. Receives &#145;Notice of Allowance&#146; From United States
Patent and Trademark Office for Use of Antibodies to Gamma Interferon to Treat
Corneal Transplant Rejection</B>
</FONT>
<P><FONT size="2">LOS ANGELES, Dec 2, 2002 (BUSINESS WIRE) &#151; Advanced Biotherapy Inc. (ADVB)&nbsp;has
received a &#147;Notice of Allowance&#148; from the United States Patent and Trademark
Office (USPTO)&nbsp;for a utility patent for the use of any form of antibody to
gamma interferon to treat corneal transplant rejection. The patent is expected
to be issued within 120&nbsp;days, according to President and Chief Executive
Officer Edmond F. Buccellato.
</FONT>
<P><FONT size="2">Mr.&nbsp;Buccellato stated, &#147;This notice of allowance is another milestone for our
company as we continue to build a wall of patent protection around our
underlying technology platform. As we previously reported in the June 2002
issue of the &#145;American Journal of Ophthalmology,&#146; thirteen patients
experiencing corneal transplant rejection after corneal grafting were enrolled
in a study performed at the Scientific Research Institute of Eye Diseases of
the Russian Academy of Sciences, Moscow. In all of the patients, the corneal
transplant was typically half-transparent, edematous (watery swelling) with
cloudy vision limited to distinguishing hand movement in front of their eyes.
After standard treatment with corticosteroids, antibiotics, anti-inflammatory
drugs and vitamins produced no improvement (these treatments were stopped), the
Company&#146;s antibodies to gamma interferon (IFN-g) were administered. Within 2 to
3&nbsp;days after start of treatment, in all but three patients, transplant
transparency improved, edema dropped, and visual acuity increased. At the end
of the first week, the transplants became almost fully transparent and
inflammation of the eyes disappeared and visual acuity increased. For three of
the patients, two additional treatment courses given at approximately 1-month
intervals were required to achieve comparable improvement. This condition was
maintained in all 13 patients during an average of 7&nbsp;months of follow-up. In
one example, a 52-year-old male having keratoconus underwent corneal
transplantation during 2000. Keratoconus is a non-inflammatory eye condition
for which there is no known cure. The normally round dome-shaped cornea
progressively thins causing a cone-like bulge to develop. This results in
significant visual impairment. The cornea is the clear window of the eye and is
responsible for refracting most of the light coming into the eye. Some
keratoconus patients have described their vision as being &#145;blind with light.&#146;
In 2001, a transplant rejection reaction occurred in this patient. His vision
deteriorated, and the corneal transplant became half-transparent. When standard
treatments had no therapeutic effect, these treatments were stopped and the
Company&#146;s antibodies were administered as eyedrops. By day 3 of the treatment,
significant improvement in visual acuity was noted. The transplant became
almost completely transparent, and peripheral areas of the cornea became
significantly more transparent. Improvement was sustained through 9&nbsp;months of
follow-up. It is management&#146;s opinion that antibodies to IFN-g can be
considered safe and effective in halting corneal transplant rejection.&#148;
</FONT>
<P><FONT size="2">The USPTO issues a Notice of Allowance when a company has completed the
application and review process for a U.S. patent and has satisfied all of the
legal criteria for patentability of the invention.
</FONT>
<P><FONT size="2">Advanced Biotherapy is developing new therapeutic strategies for the treatment
of severe autoimmune diseases. Drugs that may be developed under the company&#146;s
patents neutralize immunomodulators called cytokines, which have been linked to
diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, AIDS and
other autoimmune diseases.
</FONT>
<P><FONT size="2">Statements made in this news release, other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties
that could cause actual results to differ materially from the anticipated
results or other expectations expressed in our forward-looking statements. The
risks and uncertainties which may affect the development, operations and
results of our business include, but are not limited to the following: risks
associated with clinical trials, the uncertainties of research and product
development programs, the uncertainties of the regulatory approval process, the
risks of competitive products,
</FONT>
<P align="center"><FONT size="2">&nbsp;
</FONT>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<P><FONT size="2">the risks of our current capital resources, the
uncertainties as to the availability of future capital and our future capital
requirements, and the risks associated with the extent and breadth of the
Company&#146;s patent portfolio. The foregoing discussion of the effect of the
patents issued and pending involves risks and uncertainties, including but not
limited to the risks that third parties may be successful in challenging such
patents; or that granted claims may be held invalid or interpreted differently
by a court of law; or that new technologies will be developed that are superior
in treating the diseases targeted by Advanced Biotherapy, Inc. Readers are
cautioned not to place reliance on these forward-looking statements, which
speak only as of the date the statements were made. See the Company&#146;s public
filings with the Securities and Exchange Commission for further information
about risks and uncertainties that may affect the Company and the results or
expectations expressed in our forward-looking statements, including the section
captioned &#147;Factors That May Affect The Company&#148; contained in the Company&#146;s
Annual Report on Form&nbsp;10-KSB for the fiscal year ended December&nbsp;31, 2001.
</FONT>
<P><FONT size="2">Advanced Biotherapy, Inc.<BR>
Edmond Buccellato, 818/883-6716<BR>
www.advancedbiotherapy.com
</FONT>

<P align="center"><FONT size="2">&nbsp;</FONT>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SUBMISSION>
